Quince Therapeutics (QNCX) Institutional Ownership $1.68 -0.01 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 08/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)CurrentInstitutional OwnershipPercentage30.75%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$1.84MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$27.15K Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNCX Institutional Buying and Selling by Quarter Quince Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2025Ieq Capital LLC806,780$1.07M0.0%N/A1.828% 5/12/2025Virtu Financial LLC43,332$58K0.0%+48.4%0.098% 4/11/2025Intellectus Partners LLC53,312$71K0.0%N/A0.121% 2/17/2025Two Sigma Investments LP30,341$57K0.0%N/A0.069% 2/17/2025Shay Capital LLC276,799$518K0.1%+60.8%0.629% 2/14/2025Northern Trust Corp50,524$94K0.0%+48.5%0.115% 2/12/2025Geode Capital Management LLC375,932$703K0.0%+10.9%0.854% 2/11/2025Virtu Financial LLC29,204$55K0.0%N/A0.066% 2/5/2025Anfield Capital Management LLC26,656$50K0.0%N/A0.061% 1/24/2025 Scharf Investments LLC91,061$170K0.0%N/A0.207% 11/16/2024Geode Capital Management LLC339,125$263K0.0%+24.2%0.784% 8/9/2024Renaissance Technologies LLC483,902$363K0.0%-7.0%1.120% 1/12/2024 Scharf Investments LLC91,061$96K0.0%N/A0.212% 7/31/2023Intellectus Partners LLC53,527$81K0.0%N/A0.148% 7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892% 5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642% 4/20/2023Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086% (Data available from 1/1/2016 forward) QNCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNCX shares? During the previous two years, 10 institutional investors and hedge funds held shares of Quince Therapeutics. The most heavily invested institutionals were Ieq Capital LLC ($1.07M), Geode Capital Management LLC ($703K), Shay Capital LLC ($518K), Renaissance Technologies LLC ($363K), Scharf Investments LLC ($170K), Northern Trust Corp ($94K), and Intellectus Partners LLC ($71K).Learn more on Quince Therapeutics' institutional investors. What percentage of Quince Therapeutics' stock is owned by institutional investors? 30.75% of Quince Therapeutics' stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings. Which institutional investors have been buying Quince Therapeutics' stock? Of the 9 institutional investors that purchased Quince Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Ieq Capital LLC ($806.78K), Scharf Investments LLC ($182.12K), Shay Capital LLC ($104.62K), Geode Capital Management LLC ($102.98K), Intellectus Partners LLC ($53.31K), Virtu Financial LLC ($43.33K), and Two Sigma Investments LP ($30.34K). How much institutional buying is happening at Quince Therapeutics? Institutional investors have bought a total of 1,275,576 shares in the last 24 months. This purchase volume represents approximately $1.84M in transactions. Which of Quince Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Quince Therapeutics stock in the last 24 months: Renaissance Technologies LLC ($36.20K). How much institutional selling is happening at Quince Therapeutics? Institutional investors have sold a total of 36,198 shares in the last 24 months. This volume of shares sold represents approximately $27.15K in transactions. Related Companies Rocket Pharmaceuticals Major Shareholders Inhibrx Biosciences Major Shareholders Abeona Therapeutics Major Shareholders Atea Pharmaceuticals Major Shareholders Altimmune Major Shareholders Allogene Therapeutics Major Shareholders ADC Therapeutics Major Shareholders Neurogene Major Shareholders Capricor Therapeutics Major Shareholders Olema Pharmaceuticals Major Shareholders This page (NASDAQ:QNCX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
